首页> 外文期刊>Surgical Endoscopy >Total laparoscopic liver resection for hepatocellular carcinoma located in all segments of the liver.
【24h】

Total laparoscopic liver resection for hepatocellular carcinoma located in all segments of the liver.

机译:肝细胞癌的所有腹腔镜全腹腔镜肝脏切除术。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Laparoscopic liver resection (LLR) is still not a well-established treatment modality for hepatocellular carcinoma (HCC). Moreover, most reported cases have been limited to tumors in the anterolateral (AL) segments (segments 2, 3, 4b, 5, and 6). We evaluated clinical and oncologic outcomes after LLR for HCC located in all segments, including lesions located in the posterosuperior (PS) segments (segments 1, 4a, 7, and 8). METHODS: This retrospective study included 69 patients who had undergone LLR for HCC between September 2003 and November 2008. The patients were divided into two groups (group AL and group PS) according to tumor location. The clinical data of the two groups were retrospectively analyzed. RESULT: There was no postoperative mortality. Fifteen patients (21.7%) experienced 19 postoperative complications. During a median follow-up period of 21.3 months, recurrence was detected in 21 (30.4%) patients. The 3-year overall survival rate and disease-free survival rate were 90.4 and 60.4%, respectively. There was no difference in clinicopathologic characteristics between the two groups except for a male predominance in group PS (p = 0.021) and that there were more patients with thrombocytopenia in group AL (p = 0.001). Although group PS patients had longer operative time (p = 0.001) and longer postoperative hospital stay (p = 0.039), along with a tendency toward a higher rate of open conversion (p = 0.054) and greater blood loss (p = 0.068), there was no significant difference in rates of postoperative complications (p = 0.375), recurrence (p = 0.740), 3-year overall survival (p = 0.237) or disease-free survival (p = 0.411) between the two groups. CONCLUSIONS: Our experience shows that LLR can be safely performed in selected patients with HCC located in all segments of the liver, including the posterosuperior segments, with acceptable postoperative morbidity and oncologic results.
机译:背景:腹腔镜肝切除术(LLR)仍不是公认的治疗肝细胞癌(HCC)的方法。此外,大多数报道的病例仅限于前外侧(AL)节段(2、3、4b,5和6段)的肿瘤。我们对所有部位的肝癌进行LLR后评估了临床和肿瘤学结局,包括位于后上(PS)部位(第1、4a,7和8段)的病变。方法:这项回顾性研究纳入了自2003年9月至2008年11月在LCC进行HCC的69例患者。根据肿瘤位置将其分为两组(AL组和PS组)。回顾性分析两组的临床资料。结果:没有术后死亡率。 15名患者(21.7%)经历了19例术后并发症。在21.3个月的中位随访期内,有21例(30.4%)患者被发现复发。 3年总生存率和无病生存率分别为90.4%和60.4%。两组之间的临床病理特征没有差异,除了PS组中男性占优势(p = 0.021),AL组中血小板减少症的患者更多(p = 0.001)。尽管PS组患者手术时间更长(p = 0.001)和术后住院时间更长(p = 0.039),并且有更高的开放转换率(p = 0.054)和更多的失血(p = 0.068),两组的术后并发症发生率(p = 0.375),复发率(p = 0.740),3年总生存率(p = 0.237)或无病生存率(p = 0.411)没有显着差异。结论:我们的经验表明,LLR可在部分肝癌患者中,包括肝脏的后上段,安全地进行LCC手术,并具有可接受的术后发病率和肿瘤学结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号